EyePoint Pharmaceuticals' LUCIA Phase III Wet AMD Trial Misses Primary Endpoint
EyePoint Pharmaceuticals reported that its Phase III LUCIA trial of DURAVYU (vorolanib intravitreal insert) for wet age-related macular degeneration did not achieve the primary non-inferiority endpoint for mean change in best-corrected visual acuity versus on-label aflibercept. The company reported visual improvement and a 38% reduction in treatment burden versus aflibercept, while the related LUGANO trial had also previously missed its primary endpoint.
The initial record misidentifies the sponsor as Ocular Therapeutix. The source title carries ticker EYPT, and corroborating reports explicitly identify EyePoint Pharmaceuticals' DURAVYU program and state that LUCIA failed its primary BCVA non-inferiority endpoint versus on-label aflibercept; therefore the company and development are corrected. The current atomic update is the LUCIA result, while LUGANO's earlier endpoint miss is retained only as related program context. The unrelated future DME readouts are omitted. This is a material forward-looking clinical, regulatory, and commercialization update rather than price commentary, warranting high importance. Surprise is material but not maximal because market expectations are not provided. Core facts are well corroborated, although the exact occurrence time is estimated from reporting timestamps. EYPT is directly affected; REGN and BAYRY are explicit Eylea/aflibercept comparator beneficiaries, and OCUL is a directly relevant long-acting wet-AMD competitor. More remote and speculative read-throughs are excluded.
LUGANO and LUCIA missed their primary non-inferiority endpoint, although safety, fluid control and injection-burden results were encouraging.